Results 81 to 90 of about 3,302 (197)

JAK Inhibitor and Crohn’s Disease

Biomedicines
Crohn’s disease is a chronic inflammatory granulomatous disease of the gastrointestinal tract. The global incidence and prevalence of Crohn’s disease have significantly increased, largely due to genetic susceptibility, environmental changes, and ...
Mengyan Xu, Shi Wang, Sanping Xu, Rui Gong   +3 more
doaj   +1 more source

Targeted therapy of inflammatory bowel diseases: realities and prospects

Медицинский совет, 2018
This review article was designed to systematize the literature data concerning the role of targeted therapy in the treatment of patients with inflammatory bowel diseases.
I. V. Maev, D. N. Andreev
doaj   +1 more source

A Phase Ib Investigator-Initiated Trial of Filgotinib in Patients With Idiopathic Multicentric Castleman Disease

Cureus
Background Idiopathic multicentric Castleman disease (iMCD) is a chronic systemic inflammatory disease characterized by the production of interleukin (IL)-6.
S. Fukui, R. Sumiyoshi, Tomohiro Koga, N. Hosogaya, Sawana Narita, S. Morimoto, Hiroshi Yano, Atsushi Katsube, S. Yano, Y. Masaki, Shinichiro Tsunoda, S. Sato, Kiyoshi Migita, Kazuko Matsuyama, Naoki Kato, Atsuhiko Kawamoto, A. Kawakami   +16 more
semanticscholar   +1 more source

Positioning filgotinib in the therapeutic landscape of rheumatoid arthritis - alternative or complementary?

Ulusal Romatoloji Dergisi
Rheumatoid arthritis is a chronic inflammatory disease characterized by persistent immune activation and progressive joint damage. Although conventional and biological disease-modifying antirheumatic drugs have substantially improved disease control ...
Rukiye Menemencioğlu, Burcu Şahinbaş, Ahmet Altun   +2 more
doaj   +1 more source

Correction to: Filgotinib: First Approval [PDF]

Drugs, 2021
Dhillon, Sohita, Keam, Susan J.
openaire   +1 more source

Interindividual variability and its impact on the effectiveness of Janus kinase inhibitors in rheumatoid arthritis treatment

Frontiers in Medicine
IntroductionAchieving the primary treat-to-target (T2T) goal in rheumatoid arthritis (RA) remains challenging for many patients, reflecting limitations in the effectiveness of existing treatments. Our study examines factors influencing Janus kinase (JAK)
Cristina Martinez-Molina, Cristina Martinez-Molina, Silvia Vidal, Silvia Vidal, Cesar Diaz-Torne, Cesar Diaz-Torne, Cesar Diaz-Torne, Hye S. Park, Hye S. Park, Hye S. Park, Hèctor Corominas, Hèctor Corominas, Hèctor Corominas   +12 more
doaj   +1 more source

Efficacy and safety of filgotinib in the treatment of ulcerative colitis with a focus on rapid and sustained efficacy: a narrative review.

Intestinal Research
The rising incidence of ulcerative colitis (UC) globally highlights the necessity for treatment strategies that extend beyond symptom control to include inducing and maintaining remission, achieving biochemical and endoscopic remission, and restoring ...
T. Hisamatsu, T. Kaise, Chisa Nagakura, M. Kamiya, Shu-Chen Wei   +4 more
semanticscholar   +1 more source

Experimental and Investigational Pharmacotherapy for Psoriatic Arthritis: Drugs of the Future

Journal of Experimental Pharmacology, 2020
Luca Navarini,1,* Damiano Currado,1,* Luisa Costa,2 Marco Tasso,2 Maria Sole Chimenti,3 Francesco Caso2 1Unit of Rheumatology, Immunology and Clinical Medicine, Università Campus Bio-Medico Di Roma, Rome, Italy; 2Rheumatology Unit, Department of ...
Navarini L, Currado D, Costa L, Tasso M, Chimenti MS, Caso F   +5 more
doaj  

Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years

Annals of the Rheumatic Diseases
Objectives To update the long-term safety profile of filgotinib, a Janus kinase-1 preferential inhibitor, in patients with moderate-to-severe rheumatoid arthritis.
Gerd R. Burmester, J. Gottenberg, R. Caporali, Kevin L. Winthrop, Yoshiya Tanaka, E. V. Ekoka Omoruyi, V. Rajendran, P. Van Hoek, K. Van Beneden, Tsutomu Takeuchi, René Westhovens, D. Aletaha   +11 more
semanticscholar   +1 more source

Efficacy and Safety of Filgotinib for the Treatment of Perianal Fistulising Crohn’s Disease [DIVERGENCE 2]: A Phase 2, Randomised, Placebo-controlled Trial

Journal of Crohn's & Colitis
Background and Aims There is an unmet need in the treatment of perianal fistulising Crohn’s disease [PFCD]. This study evaluated the efficacy and safety of the Janus kinase 1 preferential inhibitor, filgotinib, for the treatment of PFCD.
W. Reinisch, J. Colombel, G. D’Haens, J. Rimola, T. Masior, M. McKevitt, Xuehan Ren, A. Serone, David A. Schwartz, K. Gecse   +9 more
semanticscholar   +1 more source